BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abrams SL, Lertpiriyapong K, Yang LV, Martelli AM, Cocco L, Ratti S, Falasca M, Murata RM, Rosalen PL, Lombardi P, Libra M, Candido S, Montalto G, Cervello M, Steelman LS, Mccubrey JA. Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Advances in Biological Regulation 2018;69:16-34. [DOI: 10.1016/j.jbior.2018.06.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Makler A, Narayanan R, Asghar W. An Exosomal miRNA Biomarker for the Detection of Pancreatic Ductal Adenocarcinoma. Biosensors (Basel) 2022;12:831. [PMID: 36290970 DOI: 10.3390/bios12100831] [Reference Citation Analysis]
2 McCubrey JA, Yang LV, Abrams SL, Steelman LS, Follo MY, Cocco L, Ratti S, Martelli AM, Augello G, Cervello M. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Cells 2022;11:2155. [PMID: 35883598 DOI: 10.3390/cells11142155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Abrams SL, Duda P, Akula SM, Steelman LS, Follo ML, Cocco L, Ratti S, Martelli AM, Montalto G, Emma MR, Cervello M, Rakus D, Gizak A, Mccubrey JA. Effects of the Mutant TP53 Reactivator APR-246 on Therapeutic Sensitivity of Pancreatic Cancer Cells in the Presence and Absence of WT-TP53. Cells 2022;11:794. [DOI: 10.3390/cells11050794] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Abrams SL, Akula SM, Steelman LS, Follo ML, Cocco L, Ratti S, Martelli AM, Libra M, Falzone L, Candido S, Montalto G, Cervello M, Lombardi P, McCubrey JA. Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Adv Biol Regul 2021;:100840. [PMID: 34866036 DOI: 10.1016/j.jbior.2021.100840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Marvi MV, Mongiorgi S, Ramazzotti G, Follo MY, Billi AM, Zoli M, Mazzatenta D, Morandi L, Asioli S, Papa V, McCubrey JA, Suh PG, Manzoli L, Cocco L, Ratti S. Role of PLCγ1 in the modulation of cell migration and cell invasion in glioblastoma. Adv Biol Regul 2021;:100838. [PMID: 34819252 DOI: 10.1016/j.jbior.2021.100838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Wang H, Ding W, Shi H, Bao H, Lu Y, Jiang TA. Combination therapy with low-frequency ultrasound irradiation and radiofrequency ablation as a synergistic treatment for pancreatic cancer. Bioengineered 2021. [PMID: 34696663 DOI: 10.1080/21655979.2021.1995581] [Reference Citation Analysis]
7 van der Sijde F, Azmani Z, Besselink MG, Bonsing BA, de Groot JWB, Groot Koerkamp B, Haberkorn BCM, Homs MYV, van IJcken WFJ, Janssen QP, Lolkema MP, Luelmo SAC, Mekenkamp LJM, Mustafa DAM, van Schaik RHN, Wilmink JW, Vietsch EE, van Eijck CHJ. Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. Ther Adv Med Oncol 2021;13:17588359211033704. [PMID: 34422118 DOI: 10.1177/17588359211033704] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Abrams SL, Akula SM, Martelli AM, Cocco L, Ratti S, Libra M, Candido S, Montalto G, Cervello M, Gizak A, Rakus D, Steelman LS, McCubrey JA. Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Adv Biol Regul 2021;79:100780. [PMID: 33451973 DOI: 10.1016/j.jbior.2020.100780] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
9 Lin S, Zhou J, Xiao Y, Neary B, Teng Y, Qiu P. Identification of Protein Markers Predictive of Drug-Specific Survival Outcome in Cancers. Bioinformatics Research and Applications 2021. [DOI: 10.1007/978-3-030-91415-8_6] [Reference Citation Analysis]
10 Maffucci T, Falasca M. Inositol Polyphosphate-Based Compounds as Inhibitors of Phosphoinositide 3-Kinase-Dependent Signaling. Int J Mol Sci 2020;21:E7198. [PMID: 33003448 DOI: 10.3390/ijms21197198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chappell WH, Candido S, Abrams SL, Akula SM, Steelman LS, Martelli AM, Ratti S, Cocco L, Cervello M, Montalto G, Nicoletti F, Libra M, McCubrey JA. Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. Aging (Albany NY) 2020;12:10194-210. [PMID: 32492656 DOI: 10.18632/aging.103377] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
12 Akula SM, Ruvolo PP, McCubrey JA. TP53/miR-34a-associated signaling targets SERPINE1 expression in human pancreatic cancer. Aging (Albany NY) 2020;12:2777-97. [PMID: 31986125 DOI: 10.18632/aging.102776] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
13 Akula SM, Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Cocco L, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Murata RM, Rosalen PL, Bueno-silva B, Matias de Alencar S, Falasca M, Montalto G, Cervello M, Notarbartolo M, Gizak A, Rakus D, Libra M, Mccubrey JA. Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells. Advances in Biological Regulation 2020;75:100672. [DOI: 10.1016/j.jbior.2019.100672] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Pan Q, Zhou R, Su M, Li R. The Effects of Plumbagin on Pancreatic Cancer: A Mechanistic Network Pharmacology Approach. Med Sci Monit 2019;25:4648-54. [PMID: 31230062 DOI: 10.12659/MSM.917240] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
15 Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Bueno-silva B, de Alencar SM, Lombardi P, Mao W, Montalto G, Cervello M, Rakus D, Gizak A, Lin H, Libra M, Akula SM, Mccubrey JA. Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals. Advances in Biological Regulation 2019;72:22-40. [DOI: 10.1016/j.jbior.2019.03.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
16 Adamska A, Ferro R, Lattanzio R, Capone E, Domenichini A, Damiani V, Chiorino G, Akkaya BG, Linton KJ, De Laurenzi V, Sala G, Falasca M. ABCC3 is a novel target for the treatment of pancreatic cancer. Adv Biol Regul. 2019;. [PMID: 31053501 DOI: 10.1016/j.jbior.2019.04.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
17 Akula SM, Candido S, Libra M, Abrams SL, Steelman LS, Lertpiriyapong K, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Murata RM, Rosalen PL, Bueno-Silva B, Matias de Alencar S, Montalto G, Cervello M, Gizak A, Rakus D, Mao W, Lin HL, Lombardi P, McCubrey JA. Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Adv Biol Regul 2019;73:100633. [PMID: 31047842 DOI: 10.1016/j.jbior.2019.04.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
18 Domenichini A, Edmands JS, Adamska A, Begicevic RR, Paternoster S, Falasca M. Pancreatic cancer tumorspheres are cancer stem-like cells with increased chemoresistance and reduced metabolic potential. Adv Biol Regul. 2019;72:63-77. [PMID: 30853342 DOI: 10.1016/j.jbior.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
19 Abrams SL, Follo MY, Steelman LS, Lertpiriyapong K, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Murata RM, Rosalen PL, Montalto G, Cervello M, Gizak A, Rakus D, Mao W, Lombardi P, Mccubrey JA. Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Advances in Biological Regulation 2019;71:172-82. [DOI: 10.1016/j.jbior.2018.10.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]